RVMD at a glance
Revolution Medicines Inc (RVMD, SEC CIK 1628171) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Revolution Medicines Inc (RVMD) reported revenue of $0 and a net loss of $1.1 billion. Diluted EPS was -$5.95.
- As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Revolution Medicines Inc (RVMD) shares worth $12.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Kelsey Stephen Michael on November 16, 2026 of 11,542 shares at $166.75 per share.
- In the last 90 days, RVMD insiders reported 0 open-market purchases ($0) and 74 open-market sales ($60.0M) on Form 4, a net sale of $60.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 74 sells
- Net −$60.0M
- 13F holders
- 34 funds
- $12.4B · −2 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $197.6M, versus $0 YoY, reflecting RASONQUE launch and channel stocking
- Net loss $407.5M vs $305.2M YoY, operating margin -188.9% vs not applicable
- Best program RASONQUE revenue $197.6M; highest R&D increase zoldonrasib, $78.1M vs $30.9M YoY
- Cash, equivalents and marketable securities $3.7B; operating cash use $1.2B for nine months
- Outlook: R&D and SG&A expected to increase, RASONQUE sales partial-quarter and future cost of sales percentage rising
Risk Factors
- Newly added commercialization risk: RASONQUE U.S. launch in August 2026 created limited commercial-scale manufacturing and marketing experience
- Most material financing update: $250.0 million Term Loan Facility tranche drawn in October 2026, secured by substantially all assets including intellectual property
- Regulatory pricing risk: September 2026 Globe rule would tie Medicare rebates to most-favored-nation pricing, subject to legal challenges
- Near-term market risk: RASONQUE competes with established chemotherapy and targeted therapies with greater commercial infrastructure
- Financial risk: $500.0 million 2033 Notes plus approximately $572.3 million royalty liabilities outstanding at September 30, 2026
AI summary of the RVMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- RASONQUE U.S. launch generated $197.6 million revenue in roughly five weeks, establishing Revolution Medicines as a commercial-stage oncology company
- More than 5,000 patients received RASONQUE, while payer claims covered over 90% of U.S. PDAC lives, supporting early access momentum
Item 8.01: Other Events
- FDA approval of RASONQUE triggered $250.0M Tranche A borrowing from Royalty Pharma
- $5.0M draw fee, floating interest at three-month Term SOFR plus 5.75%, with 3.50% floor
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 flags a new direct financial obligation tied to the Royalty Pharma Tranche A Loan
- Loan terms, borrowing amount, interest rate, maturity and purpose appear under Item 8.01
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 references Item 1.01 for the underlying lease-related financial obligations
- Potential future commitments tied to Phase II closing, leases, build-out, relocation and occupancy costs
Item 1.01: Entry into a Material Definitive Agreement
- New headquarters: 672,000 square feet across four Redwood City buildings, with staggered occupancy beginning September 2027
- Initial lease terms through September 2042, with three additional five-year extension options at fair market rent
AI summaries of RVMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RVMD
Don't miss the next RVMD filing
- Alerts as it files. A push when RVMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RVMD, by share count.
- Ask anything. An AI agent that reads every RVMD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kelsey Stephen Michael | Sell | Nov 16, 2026 | 11,542 | $166.75 |
| Kelsey Stephen Michael | Sell | Nov 16, 2026 | 200 | $171.65 |
| Kelsey Stephen Michael | M | Nov 16, 2026 | 27,160 | - |
| Kelsey Stephen Michael | Sell | Nov 16, 2026 | 3,627 | $167.66 |
| Kelsey Stephen Michael | Sell | Nov 16, 2026 | 3,052 | $169.46 |
| Kelsey Stephen Michael | Sell | Nov 16, 2026 | 700 | $170.40 |
| Kelsey Stephen Michael | M | Nov 16, 2026 | 27,160 | $18.56 |
| Kelsey Stephen Michael | Sell | Nov 16, 2026 | 8,039 | $168.64 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $11.6M | $0 | $0 |
| Operating Income | - | -$689.5M | -$1.2B |
| Net Income | -$436.4M | -$600.1M | -$1.1B |
| Net Margin | -3768.3% | - | - |
| Balance Sheet | |||
| Total Assets | - | $2.6B | $2.4B |
| Equity | $1.8B | $2.3B | $1.6B |
| ROE | -23.9% | -26.5% | -69.3% |
| Per Share | |||
| EPS | - | $-3.58 | $-5.95 |
| Cash Flow | |||
| Operating CF | - | -$557.4M | -$897.7M |
| CapEx | $7.7M | $10.3M | $16.0M |
Source: XBRL data in Revolution Medicines Inc (RVMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RVMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 34 | $12.40B |
| Q2 2026 | 36 | $13.12B |
| Q1 2026 | 34 | $5.80B |
| Q4 2025 | 29 | $4.73B |
| Q3 2025 | 31 | $2.95B |
| Q2 2025 | 31 | $2.28B |
| Q1 2025 | 26 | $1.66B |
| Q4 2024 | 22 | $1.70B |
- JPMorgan Chase & Co+1.45M (+44%)
- Bank of America Corp+730.8K (+74%)
- Citadel Advisors LLC+721.1K (+122%)
- Franklin Resources+468.7K (+31%)
- Raymond James Financial+366.3K (+210%)
- Goldman Sachs Group−737.0K (-35%)
- Two Sigma Investments−646.1K (-88%)
- T. Rowe Price Group−412.8K (-17%)
- Alphabet Inc−272.7K (-9%)
- Vanguard Portfolio Management LLC−137.8K (-2%)
- FMR LLC (Fidelity)−12.20M
- D.E. Shaw & Co−12.4K
- Equitable Holdings Inc−5.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 243 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RVMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 28, 2026 | - | - | - |
| 8-K | Oct 13, 2026 | - | Analysis | - |
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 28, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
RVMD SEC filings: frequently asked questions
Are RVMD insiders buying or selling?
In the last 90 days, Revolution Medicines Inc (RVMD) officers, directors and 10% owners reported no open-market purchases and 74 open-market sales worth $60.0 million by 9 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold RVMD stock?
As of September 30, 2026, the largest Revolution Medicines Inc (RVMD) holders among the 13F filers tracked by SignalX were BlackRock ($2.8 billion), Vanguard Capital Management LLC ($1.9 billion), Vanguard Portfolio Management LLC ($1.7 billion), State Street Corp ($1.0 billion), JPMorgan Chase & Co ($973.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was RVMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Revolution Medicines Inc (RVMD) reported revenue of $0 and a net loss of $1.1 billion. Diluted EPS was -$5.95. The figures come from the XBRL data in the 10-K.
What did RVMD report in its latest 8-K?
Revolution Medicines Inc (RVMD) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest RVMD SEC filings?
Revolution Medicines Inc (RVMD) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 18, 2026.
What is RVMD's SEC CIK number?
Revolution Medicines Inc (RVMD)'s SEC Central Index Key (CIK) is 1628171. EDGAR lists every RVMD filing under that number.
Ask anything about RVMD
The research agent reads RVMD's filings, financials, insider trades and 13F holders, then answers with sources.